Quick Answer
Adaptive Biotechnologies Corp reported Operating Income Loss of -$57.12 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +64.9% in Operating Income Loss from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$13.31 million | Q3 2018: -$9.16 million | Q1 2019: -$20.05 million | Q2 2019: -$16.11 million | Q3 2019: -$18.05 million | Q1 2020: -$34.62 million | Q2 2020: -$36.91 million | Q3 2020: -$37.05 million | Q1 2021: -$41.28 million | Q2 2021: -$49.77 million | Q3 2021: -$56.33 million | Q1 2022: -$63.07 million | Q2 2022: -$52.50 million | Q3 2022: -$45.43 million | Q1 2023: -$57.19 million | Q2 2023: -$47.82 million | Q3 2023: -$50.96 million | Q1 2024: -$48.76 million | Q2 2024: -$47.32 million | Q3 2024: -$32.63 million | Q1 2025: -$29.60 million | Q2 2025: -$25.04 million | Q3 2025: $10.29 million.
- Over the full 9 years of available data (2017 to 2025), Adaptive Biotechnologies Corp's Operating Income Loss has declined by 28.4%.
- Historical annual values: Fiscal year 2025: -$57.12 million | Fiscal year 2024: -$162.55 million | Fiscal year 2023: -$227.04 million | Fiscal year 2022: -$200.19 million | Fiscal year 2021: -$208.97 million | Fiscal year 2020: -$152.82 million | Fiscal year 2019: -$78.39 million | Fiscal year 2018: -$49.76 million | Fiscal year 2017: -$44.48 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: